Manufacturer Unither Pharmaceuticals has recently acquired the Novartis plant in São Paulo, Brazil (pictured), as a new step in its industrial expansion in Brazil.
“This acquisition enables us to benefit from sterile operations in Latin America and to enlarge our offer to multidose ophthalmic containers,” said Eric Goupil, President of Unither Pharmaceuticals.
“We are pleased to welcome the 180 people joining Unither Pharmaceuticals and bring new possibilities to our customers,” continued Goupil.
Unither Pharmaceuticals has a major interest in the fast-growing ophthalmology market. Thus, ongoing investments are being made, including the acquisition of this new plant in Latin America, which allows the company to manufacture ophthalmic healthcare products across four continents (Europe, Asia, North America, and South America).
We are pleased to welcome the 180 people joining Unither Pharmaceuticals and bring new possibilities to our customer
- Eric Goupil, President of Unither Pharmaceuticals
Unither Pharmaceuticals was established in Amiens, France, in 1993 and specialises in the development and manufacturing of liquid single-dose forms (particularly eye drops, saline solutions, and asthma medications in BFS unit doses and OTC and Rx formulations in stick packs) for pharmaceutical companies and generic manufacturers.
Novartis recently announced the acquisition of a US-based biopharmaceutical company focused on the discovery of precision medicines for kidney diseases named Chinook Therapeutics.
